Dr. John Pesando, MD

NPI: 1477150969
Total Payments
$12.8M
2024 Payments
$2.4M
Companies
2
Transactions
84

Payment Breakdown by Category

Royalty/License$12.8M (100.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Royalty or License $12.8M 84 100.0%

Top Paying Companies

Company Total Records Latest Year
Beckman Coulter, Inc. $12.3M 10 $0 (2024)
Becton, Dickinson and Company $468,239 74 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $2.4M 18 Beckman Coulter, Inc. ($2.2M)
2023 $2.8M 15 Beckman Coulter, Inc. ($2.6M)
2022 $2.7M 18 Beckman Coulter, Inc. ($2.6M)
2021 $2.5M 17 Beckman Coulter, Inc. ($2.5M)
2020 $2.4M 16 Beckman Coulter, Inc. ($2.4M)

All Payment Transactions

84 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
10/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $19,675.53 General
Category: Reagents
10/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $15,680.09 General
Category: Reagents
10/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $445.99 General
Category: Reagents
10/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $42.32 General
Category: Reagents
07/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $19,904.29 General
Category: Reagents
07/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $15,986.40 General
Category: Reagents
07/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $1,319.88 General
Category: Reagents
07/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $18.00 General
Category: Reagents
04/26/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $14,105.39 General
Category: Reagents
04/26/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $12,044.22 General
Category: Reagents
04/26/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $154.03 General
Category: Reagents
04/26/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $13.54 General
Category: Reagents
04/08/2024 Beckman Coulter, Inc. NAVIOS (Device), Cytomics FC500, AQUIOS Royalty or License Cash or cash equivalent $1,912,453.10 General
Category: Devices
04/02/2024 Beckman Coulter, Inc. AQUIOS (Device), NAVIOS, Cytomics FC500 Royalty or License Cash or cash equivalent $330,203.53 General
Category: Devices
01/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $12,096.45 General
Category: Reagents
01/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $10,584.89 General
Category: Reagents
01/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $1,449.72 General
Category: Reagents
01/25/2024 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $16.80 General
Category: Reagents
10/25/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $16,898.45 General
Category: Reagents
10/25/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $14,497.94 General
Category: Reagents
10/25/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $442.50 General
Category: Reagents
07/24/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $16,136.32 General
Category: Reagents
07/24/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $12,982.83 General
Category: Reagents
07/24/2023 Becton, Dickinson and Company Horizon (Device) Royalty or License Cash or cash equivalent $941.82 General
Category: Reagents
06/20/2023 Beckman Coulter, Inc. Cytomics FC500 (Device), NAVIOS, AQUIOS Royalty or License Cash or cash equivalent $2,325,766.83 General
Category: Devices

About Dr. John Pesando, MD

Dr. John Pesando, MD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/07/2020. The National Provider Identifier (NPI) number assigned to this provider is 1477150969.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Pesando, MD has received a total of $12.8M in payments from pharmaceutical and medical device companies, with $2.4M received in 2024. These payments were reported across 84 transactions from 2 companies. The most common payment nature is "Royalty or License" ($12.8M).

Practice Information

  • Specialty Hematology & Oncology
  • Location Seattle, WA
  • Active Since 10/07/2020
  • Last Updated 10/07/2020
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1477150969

Products in Payments

  • NAVIOS (Device) $6.6M
  • Cytomics FC500 (Device) $2.6M
  • FC 500 SERIES (Device) $2.2M
  • CYTOFLEX (Device) $617,470
  • AQUIOS (Device) $330,204
  • Horizon (Device) $234,086
  • BD Pharmingen (Device) $120,867
  • FACSVia (Device) $27,555
  • BD OptiBuild (Device) $22,629

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Seattle